KFG Wealth Management LLC Purchases New Shares in Johnson & Johnson (NYSE:JNJ)

KFG Wealth Management LLC acquired a new position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) in the 4th quarter, HoldingsChannel.com reports. The firm acquired 2,581 shares of the company’s stock, valued at approximately $456,000.

Several other hedge funds also recently added to or reduced their stakes in JNJ. Price T Rowe Associates Inc. MD grew its holdings in Johnson & Johnson by 18.9% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock worth $4,370,793,000 after acquiring an additional 3,912,430 shares in the last quarter. Vanguard Group Inc. grew its holdings in Johnson & Johnson by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock worth $40,078,885,000 after acquiring an additional 2,815,655 shares in the last quarter. GQG Partners LLC grew its holdings in Johnson & Johnson by 64.4% during the 1st quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after acquiring an additional 2,547,378 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its holdings in Johnson & Johnson by 52.2% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 6,102,999 shares of the company’s stock worth $1,083,329,000 after acquiring an additional 2,093,392 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its position in shares of Johnson & Johnson by 37.2% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock worth $1,179,219,000 after buying an additional 1,805,632 shares during the last quarter. 67.94% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of recent research reports. Atlantic Securities raised their price target on shares of Johnson & Johnson from $160.00 to $168.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 25th. StockNews.com initiated coverage on shares of Johnson & Johnson in a research report on Thursday, March 16th. They issued a “strong-buy” rating on the stock. UBS Group initiated coverage on shares of Johnson & Johnson in a research report on Tuesday. They issued a “neutral” rating on the stock. Piper Sandler reduced their price target on shares of Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. Finally, Morgan Stanley raised their price target on shares of Johnson & Johnson from $176.00 to $180.00 and gave the stock an “equal weight” rating in a research report on Wednesday, January 25th. Eight equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $174.73.

Johnson & Johnson Stock Performance

Want More Great Investing Ideas?

Shares of NYSE JNJ opened at $151.82 on Wednesday. The stock has a fifty day moving average price of $158.94 and a two-hundred day moving average price of $167.39. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.77 and a current ratio of 0.99. The firm has a market cap of $395.38 billion, a P/E ratio of 22.53, a PEG ratio of 2.63 and a beta of 0.54. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $186.69.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.22 by $0.13. The firm had revenue of $23.71 billion during the quarter, compared to analyst estimates of $23.90 billion. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The firm’s quarterly revenue was down 4.4% on a year-over-year basis. During the same period last year, the company posted $2.13 EPS. Research analysts forecast that Johnson & Johnson will post 10.5 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st were paid a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a dividend yield of 2.98%. The ex-dividend date was Friday, February 17th. Johnson & Johnson’s dividend payout ratio is presently 67.06%.

Insider Transactions at Johnson & Johnson

In other news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction on Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the sale, the insider now directly owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.35% of the company’s stock.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.